TY - JOUR
T1 - Viewpoint
T2 - Expanding prostate cancer screening
AU - Catalona, William J.
AU - Loeb, Stacy
AU - Han, Misop
PY - 2006/3/21
Y1 - 2006/3/21
N2 - Prostate cancer screening is controversial, and major professional associations offer differing screening guidelines. The authors address 3 key issues about prostate cancer screening: 1) the prostate-specific antigen (PSA) criteria to recommend a prostate biopsy, 2) the appropriate age to start screening, and 3) the appropriate age to stop screening. The authors argue, on the basis of evidence published since 2000, that data supporting the efficacy of PSA screening are convincing. They recommend screening for risk assessment for average-risk men beginning at age 40 years, screening selected healthy men older than age 70 years, and lowering the PSA threshold for considering biopsy to 2.5 ng/mL for all men.
AB - Prostate cancer screening is controversial, and major professional associations offer differing screening guidelines. The authors address 3 key issues about prostate cancer screening: 1) the prostate-specific antigen (PSA) criteria to recommend a prostate biopsy, 2) the appropriate age to start screening, and 3) the appropriate age to stop screening. The authors argue, on the basis of evidence published since 2000, that data supporting the efficacy of PSA screening are convincing. They recommend screening for risk assessment for average-risk men beginning at age 40 years, screening selected healthy men older than age 70 years, and lowering the PSA threshold for considering biopsy to 2.5 ng/mL for all men.
UR - http://www.scopus.com/inward/record.url?scp=33645648583&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33645648583&partnerID=8YFLogxK
U2 - 10.7326/0003-4819-144-6-200603210-00012
DO - 10.7326/0003-4819-144-6-200603210-00012
M3 - Short survey
C2 - 16549857
AN - SCOPUS:33645648583
SN - 0003-4819
VL - 144
SP - 441
EP - 443
JO - Annals of internal medicine
JF - Annals of internal medicine
IS - 6
ER -